CRIS Connect: AI4HealthyCitiesSG: Regional Blueprint on Effective Interventions in Population Health

Registration

Please register via https://for.sg/crisconnect
Registration closes Mon, 27 Oct 2025.

About the Speakers

Dr Matthew Arentz
Director
Precision Health, Novartis Foundation

As the Director of Precision Health at the Novartis Foundation, Dr Matthew Arentz leads initiatives that leverage AI and digital tools to drive advancements in predictive and preventive population health. His work involves utilizing data and modeling tools to improve overall health outcomes, focusing on precision population health across cities.

Dr Arentz is a trained physician who specialises  in pulmonary medicine, infectious diseases, and global health. He has extensive experience in health policy making, outcomes research, and modeling, working at the intersection of technology and healthcare.

Dr Arentz is passionate in improving health and healthcare for everyone, regardless of who they are and where they live.

Prof Derek Hausenloy
Executive Director
Cardiovascular Disease National Collaborative Enterprise (CADENCE)
Consortium for Clinical Research and Innovation, Singapore (CRIS)

Research Director and Senior Consultant
National Health Resarch Institute Singapore
National Health Centre Singapore (NHCS)

Faculty Professor
Cardiovascular & Metabolic Disorders Signature Programme
Duke-NUS Medical School

As the Executive Director of CADENCE, Prof Derek Hausenloy leads the integration of existing research capabilities across academic and public health institutes in order to propel Singapore to be a global leader in cardiovascular research.

Prof Hausenloy is also a Research Director and Senior Consultant at the National Heart Centre Singapore (NHCS). On top of his clinical appointment and directorships, he holds an academic appointment at Duke-NUS Medical School as a Professor for the Cardiovascular & Metabolic Disorders Signature Programme.

Prof Hausenloy is a National Medical Research Council STaR Investigator Awardee who has been a PI for more than 40 research grants. He has authored over 400 papers (H-index 115), and was named Highly Cited Researcher by Clarivate Analytics (awarded to the top 0.1% of researchers worldwide) in 2018, 2020-2025).

His main research focus is on discovering novel therapies for protecting the heart against acute ischaemia/reperfusion injury and heart failure.